Affiliation of authors: C. J. Yee, J. Boyd (Gynecology and Breast Research Laboratory, Departments of Surgery and Human Genetics), O. Lin (Department of Pathology), Memorial Sloan-Kettering Cancer Center, New York, NY.
Correspondence to: Jeff Boyd, Ph.D., Department of Surgery, Box 201, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021 (e-mail: boydj{at}mskcc.org).
Carcinoma of the uterine cervix is the most common gynecologic cancer encountered worldwide (1). Infection with human papillomavirus (HPV) is a major risk factor in cervical cancer, and HPV is present in nearly all cervical carcinomas examined (2). Additional recurrent genetic alterations in cervical cancer include loss of heterozygosity at several chromosomal regions, including 3p, 4p, 5p, 6p, 11q, 17p, 18q, and 19q, and gene amplification on chromosome 3q (3). However, specific genes at these loci have yet to be identified. Recently, Cappellen et al. (4) reported that the gene encoding fibroblast growth factor receptor 3 (FGFR3) is frequently mutated in cervical carcinomas, representing the most common specific molecular genetic alteration in cervical cancer identified to date.
FGFR3 is a transmembrane tyrosine kinase receptor that mediates signals for cell proliferation, differentiation, angiogenesis, and embryogenesis (57). Distinct germline missense mutations in FGFR3 result in the autosomal dominant human skeletal diseases of achondroplasia, hypochondroplasia, and thanatophoric dysplasia (8). Cappellen et al. (4) reported that the FGFR3 messenger RNA is expressed in 92% of bladder (70 of 76) and 93% of cervical (27 of 29) cancers as well as in normal urothelia and normal cervical epithelia. In addition, these authors (4) reported that 25% (three of 12) of cervical carcinomas contain the same somatic missense mutation at codon 249 of the FGFR3 gene, TCC(Ser) TGC(Cys). The S249C mutation results in the presence of a cysteine residue in the extracellular ligand-binding domain and may lead to constitutive activation of FGFR3 by ligand-independent dimerization of the receptor; when present in the germline, this mutation causes thanatophoric dysplasia, a lethal short-limb skeletal dysplasia (9). The findings that FGFR3 is commonly expressed in the cervical epithelium and that the S249C mutation is present in 25% of cervical carcinomas suggest that FGFR3 may play an important role in cervical tumorigenesis (4).
Because the number of cervical cancer specimens examined was relatively small (n = 12) in the study by Cappellen et al. (4), we sought to clarify the role of the FGFR3 S249C mutation in a larger sample of cervical carcinomas (n = 104). We analyzed tumors from a consecutive series of unselected patients who underwent primary cervical cancer surgery at this institution over a 10-year period (19901999). This study was approved by the Institutional Review Board of the Memorial Sloan-Kettering Cancer Center. Pathologic review was performed on each case to confirm a diagnosis of invasive cervical carcinoma. With regard to histologic subtype, 95 (91%) of the cervical cancers were squamous cell and nine (9%) were adenocarcinoma. With regard to surgical stage, eight were stage IA, 78 were stage IB, nine were stage IIA, five were stage IIB, two were stage IIIB, and one was stage IVB, according to criteria described previously (10). Stage was unavailable for one case. Histologic and stage distributions were typical for those generally seen in the cervical carcinoma population. After microdissection of tumor tissue from formalin-fixed, paraffin-embedded, or flash-frozen tissue specimens, genomic DNA was isolated with the use of standard procedures. A 161-base-pair polymerase chain reaction product containing codon 249 was generated with the use of the primers 5`AGTGGCGGTGGTGGTGAGGGAG-3` and 5`-TGTGCGTCACTGTACACCTTGCAG-3`, then subjected to direct sequence analysis. Of the 104 cervical carcinomas examined, all contained only the wild-type sequence (TCC) at codon 249 of FGFR3 (Fig. 1). These data suggest that the FGFR3 S249C mutation is likely to be very rare in this population of cervical carcinoma patients.
|
NOTES
Supported by a grant from the Keck Foundation.
REFERENCES
1 Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:82741.[Medline]
2 Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:129.[Medline]
3 Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999;80:200818.[Medline]
4 Cappellen D, De Oliveira C, Ricol D, de Medina SG, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:1820.[Medline]
5 Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:11565.[Medline]
6 Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993;60:141.[Medline]
7
Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995;9:91925.
8 Muenke M, Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 1995;11:30813.[Medline]
9 Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996;13:2337.[Medline]
10 Beahrs OH, Henson DE, Hutter RV, Myers MH, editors. Manual for staging of cancer. 3rd ed. Philadelphia (PA): Lippincott; 1988.
11 Helland A, Langerod A, Johnse H, Olsen AO, Skovlund E, Borrensen-Dale AL, et al. P53 polymorphism and risk of cervical cancer. Nature 1998;396:5302.[Medline]
Manuscript received April 3, 2000; revised August 28, 2000; accepted September 6, 2000.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |